# The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism

> **NCT05680662** · EARLY_PHASE1 · UNKNOWN · sponsor: **Ministry of Health, Saudi Arabia** · enrollment: 200 (estimated)

## Conditions studied

- Breast Cancer Female
- Triple Negative Breast Cancer

## Interventions

- **COMBINATION_PRODUCT:** quercetin, EGCG, metformin , zinc

## Key facts

- **NCT ID:** NCT05680662
- **Lead sponsor:** Ministry of Health, Saudi Arabia
- **Sponsor class:** OTHER_GOV
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-01-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05680662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05680662, "The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05680662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*